Implementation of raltegravir in routine clinical practice: Selection criteria for choosing this drug, virologic response rates, and characteristics of failures

Journal of Acquired Immune Deficiency Syndromes

Volumn 53, Issue 4, 2010, Pages 464-471

  Scherrer, Alexandra U ^a   Von Wyl, Viktor ^a   Fux, Christof A ^b   Opravil, Milos ^a,c   Bucher, Heiner C ^d   Fayet, Aurélie ^e   Decosterd, Laurent A ^e   Hirschel, Bernhard ^f   Khanlari, Bettina ^g   Yerly, Sabine ^f   Klimkait, Thomas ^h   Furrer, Hansjakob ^b   Ledergerber, Bruno ^a   Günthard, Huldrych F ^a  

^a UNIVERSITY HOSPITAL ZURICH   (Switzerland)

^b UNIVERSITY OF BERN   (Switzerland)

^c KLINIK HIRSLANDEN   (Switzerland)

^d UNIVERSITY HOSPITAL BASEL   (Switzerland)

^e LAUSANNE UNIVERSITY HOSPITAL   (Switzerland)

^f GENEVA UNIVERSITY HOSPITALS   (Switzerland)

^g UNIVERSITY HOSPITAL BASEL   (Switzerland)

^h UNIVERSITY OF BASEL   (Switzerland)

Author keywords

Drug resistance; Efficacy; HIV 1; Plasma concentration; Raltegravir

Indexed keywords

ENFUVIRTIDE; RALTEGRAVIR; VIRUS RNA;

ARTICLE; CD4 LYMPHOCYTE COUNT; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG RESPONSE; FEMALE; GENOTYPE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; PRIORITY JOURNAL; TREATMENT OUTCOME; VIRUS LOAD;

ANTI-HIV AGENTS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; CD4 LYMPHOCYTE COUNT; FEMALE; HIV INFECTIONS; HUMANS; MALE; PYRROLIDINONES; RANDOMIZED CONTROLLED TRIALS AS TOPIC; TREATMENT OUTCOME; VIRAL LOAD;

EID: 77949386610     PISSN: 15254135     EISSN: None     Source Type: Journal    
DOI: 10.1097/QAI.0b013e3181bca4ec     Document Type: Article

References (30)

1. Hirsch MS, Gunthard HF, Schapiro JM, et al. Antiretroviral drug resistance testing in adult HIV-1 infection: 2008 recommendations of an International AIDS Society-USA panel. Clin Infect Dis. 2008;47:266-285.
2. Tozzi V, Zaccarelli M, Bonfigli S, et al. Drug-class-wide resistance to antiretrovirals in HIV-infected patients failing therapy: prevalence, risk factors and virological outcome. Antivir Ther. 2006;11:553-560.
3. Zaccarelli M, Perno CF, Forbici F, et al. Q151M-mediated multinucleoside resistance: prevalence, risk factors, and response to salvage therapy. Clin Infect Dis. 2004;38:433-437.
4. Hazuda DJ, Young SD, Guare JP, et al. Integrase inhibitors and cellular immunity suppress retroviral replication in rhesus macaques. Science. 2004;305:528-532.
5. Cooper DA, Steigbigel RT, Gatell JM, et al. Subgroup and resistance analyses of raltegravir for resistant HIV-1 infection. N Engl J Med. 2008; 359:355-365.
6. Steigbigel RT, Cooper DA, Kumar PN, et al. Raltegravir with optimized background therapy for resistant HIV-1 infection. N Engl J Med. 2008; 359:339-354.
7. Markowitz M, Nguyen BY, Gotuzzo E, et al. Rapid and durable antiretroviral effect of the HIV-1 Integrase inhibitor raltegravir as part of combination therapy in treatment-naive patients with HIV-1 infection: results of a 48-week controlled study. J Acquir Immune Defic Syndr. 2007; 46:125-133.
8. Grinsztejn B, Nguyen BY, Katlama C, et al. Safety and efficacy of the HIV-1 integrase inhibitor raltegravir (MK-0518) in treatment-experienced patients with multidrug-resistant virus: a phase II randomised controlled trial. Lancet. 2007;369:1261-1269.
9. Lazzarin A, Clotet B, Cooper D, et al. Efficacy of enfuvirtide in patients infected with drug-resistant HIV-1 in Europe and Australia. N Engl J Med. 2003;348:2186-2195.
10. Lalezari JP, Henry K, O'Hearn M, et al. Enfuvirtide, an HIV-1 fusion inhibitor, for drug-resistant HIV infection in North and South America. N Engl J Med. 2003;348:2175-2185.
11. Haupts S, Ledergerber B, Boni J, et al. Impact of genotypic resistance testing on selection of salvage regimen in clinical practice. Antivir Ther. 2003;8:443-454.
12. Lazzarin A, Campbell T, Clotet B, et al. Efficacy and safety of TMC125 (etravirine) in treatment-experienced HIV-1-infected patients in DUET-2: 24-week results from a randomised, double-blind, placebo-controlled trial. Lancet. 2007;370:39-48.
13. Madruga JV, Cahn P, Grinsztejn B, et al. Efficacy and safety of TMC125 (etravirine) in treatment-experienced HIV-1-infected patients in DUET-1: 24-week results from a randomised, double-blind, placebo-controlled trial. Lancet. 2007;370:29-38.
14. Anderson MS, Kakuda TN, Hanley W, et al. Minimal pharmacokinetic interaction between the human immunodeficiency virus nonnucleoside reverse transcriptase inhibitor etravirine and the integrase inhibitor raltegravir in healthy subjects. Antimicrob Agents Chemother. 2008;52: 4228-4232.
15. Iwamoto M, Wenning LA, Petry AS, et al. Minimal effects of ritonavir and efavirenz on the pharmacokinetics of raltegravir. Antimicrob Agents Chemother. 2008;52:4338-4343.
16. Wenning LA, Friedman EJ, Kost JT, et al. Lack of a significant drug interaction between raltegravir and tenofovir. Antimicrob Agents Chemo-ther. 2008;52:3253-3258.
17. Iwamoto M, Wenning LA, Mistry GC, et al. Atazanavir modestly increases plasma levels of raltegravir in healthy subjects. Clin Infect Dis. 2008;47:137-140.
18. Rahal A, Soulie C, Schneider L. Therapeutic drug monitoring of raltegravir (MK-0518) in experienced HIV-infected patients. Paper presented at: 9th International Workshop on Clinical Pharmacology of HIV Therapy; 2008; New Orelans.
19. Trottier B, Walmsley S, Reynes J, et al. Safety of enfuvirtide in combination with an optimized background of antiretrovirals in treatment-experienced HIV-1-infected adults over 48 weeks. J Acquir Immune Defic Syndr. 2005;40:413-421.
20. Harris M, Larsen G, Montaner JS. Outcomes of multidrug-resistant patients switched from enfuvirtide to raltegravir within a virologically suppressive regimen. Aids. 2008;22:1224-1226.
21. Ledergerber B, Egger M, Opravil M, et al. Clinical progression and virological failure on highly active antiretroviral therapy in HIV-1 patients: a prospective cohort study. Swiss HIV Cohort Study. Lancet. 1999;353: 863-868.
22. Johnson VA, Brun-Vezinet F, Clotet B, et al. Update of the drug resistance mutations in HIV-1. Top HIV Med. 2008;16:138-145.
23. Markowitz M, Morales-Ramirez JO, Nguyen BY, et al. Antiretroviral activity, pharmacokinetics, and tolerability of MK-0518, a novel inhibitor of HIV-1 integrase, dosed as monotherapy for 10 days in treatment-naive HIV-1-infected individuals. J Acquir Immune Defic Syndr. 2006;43: 509-515.
24. Fayet A, Beguin A, Zanolari B, et al. A LC-tandem MS assay for the simultaneous measurement of new antiretroviral agents: raltegravir, maraviroc, darunavir, and etravirine. J Chromatogr B Analyt Technol Biomed Life Sci. 2009;877:1057-1069.
25. Anderson KM, Odell PM, Wilson PW, et al. Cardiovascular disease risk profiles. Am Heart J. 1991;121:293-298.
26. von Wyl V, Yerly S, Boni J, et al. Emergence of HIV-1 drug resistance in previously untreated patients initiating combination antiretroviral treatment: a comparison of different regimen types. Arch Intern Med. 2007; 167:1782-1790.
27. +patients with progressive multifocal leucoencephalopathy (ANRS CO4-FHDH). 15th Conference on Retro-viruses and Opportunistic Infections (CROI); Abstract 385; February 3-6, 2008, Boston, MA.
28. Letendre S, Marquie-Beck J, Capparelli E, et al. Validation of the CNS Penetration-Effectiveness rank for quantifying antiretroviral penetration into the central nervous system. Arch Neurol. 2008;65:65-70.
29. Letendre S, McCutchan JA, Ellis RJ. Neurologic complications of HIV disease and their treatment. Top HIV Med. 2008;16:15-22.
30. Eron JE, Andrade J, Zajdenverg R, et al. Switching from stable lopinavir/ ritanovir-based to raltegravir-based combination ART resulted in a superior lipid profile at week 12 but did not demonstrate non-inferior virologic efficacy at week 24. Paper presented at: 16th Conference on Retroviruses and Opportunistic Infections (CROI) Abstract 70aLB; February 8-11, Montreal, Canada.